Vioxx And Bextra Get Split Votes From FDA Cmte. On Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Vote slightly favors return of Vioxx to the market and continued marketing of Bextra. "Black box" warning on cardiovascular risk is recommended for COX-2s, including Pfizer's Celebrex. Restriction or banning of direct-to-consumer advertising also is advised by committee members.